Floatz logo

Peg-Intron

Advanced Fibrosis

Beth Israel Deaconess Medical CenterPhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

27 Active assets in the Advanced Fibrosis cohort.

Asset / SponsorPhaseRating
Entecavir
Tanta University
Phase 4BB
COLCHICINUM
Zagazig University
Phase 4BB
Peg-Ifn
Beijing Friendship Hospital
Phase 4BB
A THERAPEUTIC PEGYLATED FIBROBLAST GROWTH FACTOR 21 AGONIST/MIMETIC WHICH RESTORES LEPTIN RESPONSIVENESS
Bristol-Myers Squibb
Phase 2BB
Ribavirin
ANRS, Emerging Infectious Diseases
Phase 3BB

View all 50 →

Same molecule, other indications

Peg-Intron is also rated in:

hepatitis C virus infectionDormant
BB
Indicative ·
69 / 100
View asset →
melanomaDormant
B
Indicative ·
62 / 100
View asset →
cirrhosis of liverDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →